FDA approves Abrysvo for RSV in older adults

The U.S. Food and Drug Administration has approved Abrysvo (Respiratory Syncytial Virus Vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older.

“A vaccine to help prevent RSV had been an elusive public health goal for more than half a century. Today’s approval is a monumental step forward in delivering on Pfizer’s commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older adults,” said Annaliesa Anderson, PhD, Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer in a press release. “ABRYSVO will address a need to help protect older adults against the potentially serious consequences of RSV disease. We are extremely grateful to the clinical trial participants, study investigator teams and our dedicated Pfizer colleagues for their roles in making this vaccine available.”

Read the full press release here.